{"pub": "fox", "url": "https://foxbusiness.com/markets/walmart-suspends-sale-of-zantac-other-products-containing-ranitidine-over-cancer-risk", "downloaded_at": "2019-10-02 15:30:39.326308+00:00", "published_at": "2019-10-02", "title": "Walmart suspends sale of Zantac, other products containing ranitidine over cancer risk", "language": "en", "text": "Walmart will suspend the sale of Zantac and all forms of heartburn medication containing the drug ranitidine after the Food and Drug Administration warned of potential cancer risks.\n\nContinue Reading Below\n\nThe world\u2019s largest employer joins other companies including Walgreens, Rite Aid and CVS Health in halting the sale of products containing ranitidine.\n\nTicker Security Last Change Change % WMT WALMART INC. 116.77 -1.08 -0.92%\n\nLast month, the FDA said it found ranitidine, which is used in some heartburn medications like Zantac, contains N-nitrosodimethylamine (NDMA) at low levels. The federal agency said NDMA is a \u201cknown environmental contaminant\u201d that is found in water and foods like meats, dairy products and vegetables. It classifies NDMA as a substance that could cause cancer. However, it did not call for people to stop taking the medication.\n\nZantac, the brand-name version of the drug, is sold by Sanofi, but generic versions are distributed by other companies.\n\n\u201cZantac has been around for over a decade and meets all the specified safety requirements for use in the [over-the-counter] market,\u201d Sanofi said in a statement after the FDA\u2019s announcement.\n\nGET FOX BUSINESS ON THE GO BY CLICKING HERE\n\nOne distributor, Sandoz, a unit of Swiss pharma giant Novartis, halted the distribution of generic versions last month.\n\nCLICK HERE TO READ MORE ON FOX BUSINESS\n\nWalmart said customers who purchased the products can return them to Walmart stores or Sam\u2019s Club locations for a refund.", "description": "Walmart said customers who purchased the products can return them to Walmart stores or Sam\u2019s Club locations for a refund.", "authors": ["Matthew Kazin"], "top_image": "https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2019/09/0/0/zantac-iStock.jpg?ve=1&tl=1"}